JP3689099B1 - Lipase inhibitor, method for producing the same, and anti-obesity composition - Google Patents

Abstract

The present invention provides a lipase inhibitor that is safe, highly effective, and can be continuously taken on a daily basis, a method for producing the same, and a composition for anti-obesity.
A lipase inhibitor comprising as an active ingredient a lower alcohol extract of a pretreated kale which is a kale from which water-soluble components have been removed or a dried product thereof.
A pretreatment step of immersing kale or a dried product thereof in water and distributing it to water-soluble components and residues;
A method for producing a lipase inhibitor, comprising: an alcohol extraction step of immersing the residue in a lower alcohol and extracting an active ingredient with the lower alcohol.
In the production method, it is preferable that the alcohol extraction step is a step of performing heat extraction with ethanol having an ethanol concentration of 60 to 80% by volume.
An anti-obesity composition comprising the lipase inhibitor.

Description

  The present invention relates to a lipase inhibitor, a method for producing the same, and an anti-obesity composition, particularly a lipase inhibitor containing a kale component.

  Lipids taken orally are hydrolyzed by digestive enzyme lipase secreted from the pancreas and absorbed into the body. Lipids are high in energy and tend to increase in recent years, which contributes to obesity. Obesity is likely to be associated with hypertension, impaired glucose tolerance, hyperlipidemia, etc., and is considered to be a cause of ischemic heart disease, stroke, diabetes, arteriosclerosis, fatty liver, cholelithiasis, kidney disorder, etc. .

Accordingly, various lipase inhibitors having a function of inhibiting lipase activity have been developed in order to suppress lipid absorption. Various plant extracts, for example, extracts of various spices (Japanese Patent Laid-Open No. 2001-120237), yacon Extracts (Japanese Patent Laid-Open No. 2001-299272), glaze flower extracts (Japanese Patent Laid-Open No. 2002-53484), yerba mate extract (Japanese Patent Laid-Open No. 2004-161644) are disclosed as lipase inhibitors. Yes. Japanese Patent Application Laid-Open No. 03-219872 also discloses that water extracts such as bell peppers and pumpkins are effective as lipase inhibitors.
JP 2001-120237 A JP 2001-299272 A JP 2002-53484 A JP 2004-161644 A Japanese Patent Laid-Open No. 03-219872

However, in the above technique, the effect is low, the effective intake is very large, or the raw material is difficult to obtain and is expensive, and it is practically impossible to continuously ingest. there were. Such a satisfactory product has not been developed yet.
The present invention has been made in view of the above-mentioned problems of the prior art, and its object is to provide a lipase inhibitor that is safe, highly effective, and can be continuously taken on a daily basis, a method for producing the same, and a composition for anti-obesity. There is to do.

As a result of studies conducted by the present inventors in order to achieve the above object, the cruciferous plant kale acts as a lipase inhibitor, and in particular, a lower alcohol extract of kale from which water-soluble components have been removed is very effective. As a result, the present invention has been completed.
The first subject of the present invention is a lipase inhibitor containing as an active ingredient a lower alcohol extract of a pretreated kale which is a kale from which water-soluble components have been removed or a dried product thereof.

The second subject of the present invention is a pretreatment step in which kale or a dried product thereof is immersed in water and distributed into water-soluble components and residues;
An alcohol extraction step of immersing the residue in a lower alcohol and extracting an active ingredient with the lower alcohol, and a method for producing a lipase inhibitor.
In the production method, it is preferable that the alcohol extraction step is a step of performing heat extraction with ethanol having an ethanol concentration of 60 to 80% by volume.
The third subject of the present invention is an anti-obesity composition comprising the lipase inhibitor.

  According to the present invention, by extracting kale from which water-soluble components have been removed with a lower alcohol, a safe, highly effective lipase inhibitor that can be continuously ingested daily, a method for producing the same, and an anti-obesity composition Can be obtained.

Kale (Brassica oleracea var. Acephala) used in the present invention is a vegetable native to Southern Europe, and is said to be the original species of cabbage in the cruciferous plant. There are kitchen kale, mallow kale, bush kale, tree kale, collard, green leaf kanran and so on.
As the kale, fresh leaves or dried products can be used as appropriate.
The lipase inhibitor of the present invention is characterized in that a lower alcohol extract of a kale from which water-soluble components have been removed or a pre-treated kale that is a dried product thereof is used as an active ingredient.
The method for producing a lipase inhibitor of the present invention comprises a pretreatment step in which kale or a dried product thereof is immersed in water and distributed to a water-soluble component and a residue, the residue is immersed in a lower alcohol, and an active ingredient is a lower alcohol. And an alcohol extraction step of extracting at the step.
The amount of water used in the pretreatment step is not particularly limited, but is preferably about 1 to 50 times, preferably about 10 times, by mass with respect to the dried kale. If it is less than 1 time, water-soluble components may not be sufficiently removed, and if it exceeds 50 times, workability is inferior.

Examples of the lower alcohol used in the alcohol extraction step include ethanol, propanol, isopropanol, isobutyl alcohol, t-butyl alcohol, and the like. Ethanol, particularly ethanol having an ethanol concentration of 60 to 80% by volume, is used. preferable.
The amount of the lower alcohol when extracting the active ingredient is not particularly limited, but is preferably about 1 to 50 times, preferably about 10 times, by mass with respect to the dried kale material. If it is less than 1 time, the active ingredient may not be sufficiently extracted. If it exceeds 50 times, it is necessary to evaporate a large amount of alcohol, resulting in poor workability.
For example, 1 L of water is added to 100 g of dry powder of kale and heated under reflux for 1 hour. After filtration, the residue is dried, 1 L of 80 vol% ethanol is added and heated under reflux for 1 hour to obtain a lower alcohol extract.

  The lipase inhibitor of the present invention has an excellent lipase activity inhibitory action and is very safe. Therefore, by taking it on a daily basis, it suppresses the absorption of lipids in the body, and obesity and accompanying it. Diseases can be prevented and ameliorated.

The lipase inhibitor of the present invention can be ingested in the form of a solid agent such as a tablet, capsule, granule or powder; a liquid agent such as a solution, suspension or emulsion; a lyophilized preparation. These formulations can be prepared by conventional means. If necessary, for example, glucose, lactose, sucrose, starch, mannitol, dextrin, fatty acid glyceride, polyethylene glycol, hydroxyethyl starch, ethylene glycol, polyoxyethylene sorbitan fatty acid ester, amino acid, gelatin, vitamins, albumin Water, physiological saline, stabilizer, wetting agent, emulsifier, binder and the like can be added.
Further, the lipase inhibitor of the present invention can be used for various foods such as fats and oils (salad oil, butter, margarine, lard), seasonings, creams, dairy products, meats, seafood, processed meat foods (ham, sausage, etc.) It can also be ingested by adding it to processed fishery products (kamaboko, chikuwa, etc.), eggs, confectionery, beverages, bread, health foods, processed foods and the like.

The effective dose of the lipase inhibitor of the present invention is appropriately selected and determined according to the patient's age, weight, administration time, form, etc. However, since the active ingredient is condensed, a small amount can be used and it can be continued without difficulty. Can be consumed. In addition, it may be taken in several times a day, and in particular, it is preferably taken within 1 hour before and after a meal.
JP-A-2004-43375 reports that kale or an extract thereof has an antagonistic action on the NPY receptor or MCH receptor and suppresses an abnormal increase in appetite. However, it does not describe the action of inhibiting lipase activity and suppressing digestive absorption of ingested lipids. Furthermore, in the above technique, since ethanol extraction is directly performed without removing water-soluble components by water extraction, in order to obtain a sufficient obesity prevention / treatment effect, the dose is increased, and it is practically a continuous intake. Was impossible.

Furthermore, if the lipase inhibitor of the present invention is added to a food or drink containing lipids or an external preparation for skin, it can suppress degradation of lipids by lipase produced by microorganisms, and can suppress deterioration of lipids such as deteriorated odor. it can. Moreover, the lipase inhibitor of this invention can suppress decomposition | disassembly of the sebum by the lipase which a skin resident bacteria produces on skin, and can suppress a body odor and a skin disease.
Hereinafter, the present invention will be described in more detail with reference to examples. The present invention is not limited to these examples. Unless otherwise specified, the blending amount indicates mass%.

First, the following preliminary samples 1 to 7 were prepared (FIG. 1).
Preliminary sample 1 Kale dry powder (14 g) obtained by freeze-drying and pulverizing kale leaves.
Preliminary sample 2 An extract obtained by heating (refluxing) 14 g of dry kale powder with 140 mL of water for 1 hour.
Preliminary sample 3 The ethanol precipitate of the extract of Test Example 2 was dried (0.7 g)
Preliminary sample 4 14 g of dry kale powder was extracted by heating (refluxing) with 140 mL of water for 1 hour, and the residue was dried (6.6 g).
Preliminary Sample 5 6.6 g of the dry residue of Test Example 4 was heated and extracted (refluxed) with 140 mL of 80 vol% ethanol for 1 hour, and the residue was dried (5.8 g).
Preliminary Sample 6 An extract obtained by heating (refluxing) 6.6 g of the dry residue of Test Example 4 with 140 mL of 80% ethanol by volume for 1 hour.
Preliminary sample 7 An extract obtained by heating (100 ° C.) 14 g of dry kale powder with 140 mL of 80 vol% ethanol for 1 hour.

<Lipase inhibition test>
A lipase inhibition test was performed using the above sample.
(Preparation of samples for each test example)
Test Example 1: 120 mL of water was added to the preliminary sample 1.
Test Example 2: Preliminary sample 2 was subjected to a rotary evaporator, and water was appropriately removed to 120 mL.
Test Example 3 120 mL of water was added to the preliminary sample 3.
Test Example 4 120 mL of water was added to the preliminary sample 4.
Test Example 5: 120 mL of water was added to the preliminary sample 5.
Test Example 6: Preliminary sample 6 was subjected to a rotary evaporator to remove ethanol, and 120 mL of water was added.
Test Example 7: Preliminary sample 7 was subjected to a rotary evaporator to remove ethanol, and 120 mL of water was added.
(Test method)
A sample tube (0.1 mL), McIlvain buffer solution (0.7 mL), and triolein (0.1 mL) were added and stirred well. Porcine pancreatic lipase (0.1 mL) was added, and the mixture was shaken at 37 ° C. for 1 hour.
After 2 mL of ethanol was added to stop the reaction, a coloring reagent was added, the absorbance was measured at 550 nm, and the serum free fatty acid concentration was determined from the following formula.
The inhibition rate was calculated as follows (n = 3).
Serum free fatty acid concentration (mEq / L) = S / (Std-BI)
(S: sample absorbance, Std: standard, BI: reagent blind)
Lipase inhibition rate (%) = {(blank value−each sample value) / blank value} × 100

The results are shown in Table 1.
(Table 1)
Test example
1 2 3 4 5 6 7
Lipase inhibition rate (%)
73.7 47.0 0 0 0 78.9 78.0
Test Example 6 corresponds to the lipase inhibitor of the present invention.
When calculated from the difference between the yield of Test Example 4 and the yield of Test Example 5, Test Example 6 has a kale solid content of 0.8 g. This corresponds to 5.5% by weight of the original kale dry powder.
Comparing the lipase inhibition rate, surprisingly, the value of Test Example 6 was higher than that of Test Example 1 despite the small amount.
Further, when Test Example 6 and Test Example 7 are compared, in Test Example 7 extracted directly with ethanol, the kale solid content is 4.7 g, whereas in Test Example 6 extracted with ethanol after removing water-soluble components, Kale solids are obtained. It was confirmed that the equivalent lipase inhibitory effect was obtained even though the amount was 0.8 g and the amount was about 1/6. Test Example 7 includes a water-soluble component, but in Test Example 6, the water-soluble component is removed. From this, it can be seen that the effect of the lipase inhibitor of the present invention is not an effect derived from water-soluble dietary fiber that is supposed to suppress absorption of excess nutrients.
As described above, the lipase inhibitor of the present invention exhibits a high lipase inhibitory effect even though it is a lower alcohol extract of kale from which water-soluble components such as water-soluble dietary fiber have been removed. It was found to have an inhibitory effect.
The IR analysis results of Test Examples 2, 6, and 7 are shown in FIGS. 2 to 4, respectively, and the LC analysis results of Test Examples 2, 6, and 7 are shown in FIGS.

The relationship between the concentration of Kale extract and lipase inhibitory activity was examined.
(Sample preparation)
100 g of dry kale powder was heated and extracted (refluxed) with 1 L of water, and the dried residue obtained after filtration was heated (refluxed) with 1 L of 80 vol% ethanol for 1 hour, and the extract was washed with 80% ethanol to obtain a solid concentration of 2.6. , 5.2, 10.4, 20.9 (mg / mL), and using these samples, the lipase inhibitory effect at each concentration was examined in the same manner as described above. The results are shown in Table 2 below.

(Table 2)
Concentration (mg / mL) 1.6 3.2 6.3 12.6
Lipase inhibitory activity (%) 37.8 50.5 88.8 92.0
It was confirmed that the lipase inhibitory effect was increased in a concentration-dependent manner.

<Rat test>
Next, each of the above samples was administered to rats to test the anti-obesity effect.
(1) Rearing of test rats and sample administration method Preliminary rearing (6-7 weeks old)
Zucker-fatty rats gain weight rapidly from around the age of 4 weeks of age, begin to appear in an obese state that can be distinguished from normal litters in appearance, and the weight difference from normal individuals increases with age. For this reason, Zucker-fatty rats are useful as models of obesity.
Inheritance is an autosomal simple recessive inheritance mode, only individuals with homologous pathogenic genes exhibit obesity (Zucker-fatty rats), heterozygotes and wild type do not exhibit obesity (Zucker-lean rats) .
Six-week-old male Zucker-fatty rats and male Zucker-lean rats purchased from Nippon Charles River Co., Ltd. were bred with white fluorescent light in a breeding room adjusted to room temperature 22 ± 1 ° C and humidity 60 ± 10%. Light adjustment was performed for 12 hours a day (7-19 o'clock light period), and feed and tap water were freely ingested and preliminarily raised for 1 week.
After the preliminary breeding, the weight of each individual was measured, and the Zucker-fatty rats were classified into groups A to H of 5 per group so that the average values of body weights were almost equal. Two Zucker-lean rats were classified as Group I.

Sample administration method (7-17 weeks old)
Samples were administered to each group of rats in the following manner and further reared for 10 weeks to 17 weeks of age. Feed and tap water were freely given to each group. The environment of the breeding room was a temperature of 22 ± 1 ° C., a humidity of 60 ± 10%, and white fluorescent lighting for 12 hours a day (7-19 o'clock light period).
All samples were administered orally and were administered daily from 10:00 am. After administration, sterilized water was ingested freely. In any group, the feed intake did not change with sample administration.

Zucker-fatty rat group A: 2 mL of the sample of Test Example 1 is administered per kg of body weight per day.
Group B: 2 mL of the sample of Test Example 2 is administered per kg of body weight per day.
Group C: 2 mL of the sample of Test Example 3 is administered per kg of body weight per day.
Group D: 2 mL of the sample of Test Example 4 is administered per kg of body weight per day.
Group E: 2 mL of the sample of Test Example 5 is administered per kg of body weight per day.
Group F: 2 mL of the sample of Test Example 6 is administered per kg of body weight per day.
Group G: No administration
Zucker-lean rat group H: No administration

(2) Results Body weight fluctuation The body weight was measured once a week before sample administration, and the average value of the body weight of each group of rats was determined. The results are shown in FIG.
FIG. 8 shows that the Zucker-fatty rat showed a significant increase in body weight compared to the Zucker-lean rat, but compared with the Zucker-fatty rat non-administration group (Group A), the kale administration group (Groups B to G). ) Showed suppression of weight gain from around 8 weeks of age. In particular, in group F to which the lipase inhibitor of the present invention was administered, the effect of suppressing weight gain was the highest. Moreover, although weight gain was suppressed, it was not less than that of Zucker-lean rats.
From the above, it was found that a particularly excellent anti-obesity effect can be seen by administering a lower alcohol extract of kale from which water-soluble components have been removed. Moreover, the body weight was not abnormally suppressed to a value lower than that of normal rats, and it was confirmed that the administration was safe.

Blood test All rats were fasted the day before the last day of the experiment, and the next day, deep anesthesia (Nembutal, 45 mg / kg, ip) was taken, and blood was collected from the left ventricle as much as possible with a 20G blood collection needle.
Using the collected blood, biochemical tests (automatic chemical analyzer: Auto Lab, Radio lmmuno Assay method) were performed on the following items, and the average value was obtained.
The results are shown in FIG.

When comparing G group and H group in Fig. 9, Zucker-fatty rats have higher lipid-related values than Zucker-lean rats, but compared to Zucker-fatty rats untreated group (Group A). Improvement was seen in the kale administration group (B to G group).
In particular, in group F to which the lipase inhibitor of the present invention was administered, the values of neutral fat, β-lipoprotein, free cholesterol and the like were significantly lower than those in the other groups, approaching the values of group H of normal rats. In addition, compared with phospholipids and the like, which are constituents of cell membranes, β lipoprotein, which is LDL cholesterol that promotes arteriosclerosis, and neutral fat showed a large decrease rate.
From these facts, the lipase inhibitor of the present invention can be expected to have an effect of suppressing obesity and diseases associated therewith.

In addition, the values of total bilirubin and direct bilirubin useful for the diagnosis of hepatocellular injury and liver / biliary tract diseases are also significantly decreased in the F group administered with the lipase inhibitor of the present invention, and in the normal rat H group. Approached the value.
Regarding other values, no abnormality was observed due to administration of the lipase inhibitor of the present invention.

<Human clinical examination>
For 3 monitors, the sample of the above-mentioned Test Example 6 which is the lipase inhibitor of the present invention is 1.6 g per day (in terms of dry matter), or the sample of Test Example 7 is 5.5 g per day (in terms of dry matter) They were taken every day, and blood was collected before taking, at 2 weeks after taking, and at 1 month of taking, and the neutral fat level was measured. The results are shown in Table 3.

(Table 3)
After taking
Age Gender Before taking 2 weeks 1 month Taking samples
Paneler 1: 30s Male 288 151 90 Test Example 6: 1.6g
Paneler 2: 40s Male 218 111 157 Test Example 6: 1.6g
Paneler 3: 30s Male 149 133 135 Test Example 6: 1.6g
Paneler 3: 20s Female 175 133 140 Test Example 7: 5.5g

The standard range of neutral fat is 30-149 mg / dl. Three people were out of the normal range before taking, but a decrease was seen as early as the second week of taking, and all were within the standard range in the first month of taking. Surprisingly, the sample of Test Example 6 that is the lipase inhibitor of the present invention was only 1.6 g per day, but the sample of Test Example 7 was 5.5 g per day. The same effect as taking a large amount was demonstrated.
In addition, panel 3 whose originally neutral fat level was within the standard range also showed a decrease in neutral fat level due to taking it. That is, it was confirmed that a person having a neutral fat value within the standard range also acts positively within the standard range.
Therefore, even in human clinical examinations, the lipase inhibitor of the present invention exerts an excellent lipase inhibitory effect in a small amount, and the effect is not only for people with an abnormal triglyceride level but also for people within the standard range. It was confirmed that it was exhibited within the normal range. In addition, side effects such as diarrhea, vomiting, and abnormal urination did not occur by taking, and it was safe to take.

<Extraction temperature condition and lipase inhibitory effect>
Next, the relationship between the temperature of water in the water-soluble component removal step, the temperature of the lower alcohol in the alcohol extraction step, and the lipase inhibitory effect was tested.
(Sample preparation)
Test Example 9-1 (water heating extraction → ethanol heating extraction)
10 g of the dry kale powder was heated and extracted (refluxed) with 100 mL of water for 1 hour, the residue obtained after filtration was dried, and heated and extracted (refluxed) with 100 mL of 80 vol% ethanol for 1 hour.
Test Example 9-2 (water-cooled extraction → ethanol heated extraction)
10 g of dry kale powder was chilled and extracted (5 ° C.) for 48 hours with 100 mL of water, and the residue obtained after filtration was dried and heated (refluxed) with 100 mL of 80 vol% ethanol for 1 hour.
Test Example 9-3 (water refrigerated extraction → ethanol refrigerated extraction)
10 g of dry kale powder was chilled and extracted (5 ° C.) with 100 mL of water for 48 hours, and the resulting residue was dried and chilled and extracted (5 ° C.) with 100 mL of 80 vol% ethanol for 48 hours.
Test Example 9-4 (water heating extraction → ethanol refrigerated extraction)
10 g of dry kale powder was heated and extracted (refluxed) with 100 mL of water for 1 hour, and the residue obtained after filtration was dried and refrigerated and extracted (5 ° C.) for 48 hours with 100 mL of 80 vol% ethanol.

Using the extract obtained in Test Examples 9-1 to 9-4, the lipase inhibition test described above was performed, and the solid content concentration (IC50) (mg / mL) in the extract at which the lipase inhibition rate was 50%. ) Was investigated. The smaller this value, the higher the lipase inhibitory effect per certain amount.
(Table 4)
Test Example 9-1 Test Example 9-2 Test Example 9-3 Test Example 9-4
IC50 (mg / mL) 2.9 6.2 5.6 7.8
It was found that the lipase inhibitory effect was not reduced by heating, but rather a product with higher effect was obtained by heat extraction. Moreover, when ethanol extraction is performed on refrigeration conditions, the solid content obtained will decrease. Therefore, alcohol extraction is preferably performed under heating.

<Extracted alcohol concentration and lipase inhibitory effect>
Next, the relationship between the extracted alcohol concentration and the lipase inhibitory effect was tested.
100 g of dry kale powder was heated and extracted (refluxed) with 1 L of water, and the dried residue obtained after filtration was heated and extracted (refluxed) with 1 L of ethanol solution of each ethanol concentration for 1 hour to obtain an extract after filtration.
Using the obtained extract, the lipase inhibition test described above was performed, and the concentration of solid content (IC50) (mg / mL) in the extract at which the lipase inhibition rate was 50% was examined. The smaller this value, the higher the lipase inhibitory effect per fixed amount.

(Table 5)
Ethanol concentration IC50 (mg / mL)
50% by volume 11.5
60% by volume 5.0
70% by volume 5.0
80% by volume 2.9
90% by volume 7.6
99.5% by volume 6.3
When the ethanol concentration was 60 to 80% by volume, a high inhibitory effect was obtained.
Therefore, it was confirmed that the ethanol concentration is preferably 60 to 80% by volume.

<Lipase inhibitory effect of various vegetables>
About various vegetables, the lipase inhibition rate was measured like the test example 7 of Example 1 using the extract. The results are shown in Table 6.
(Table 6)
Vegetable name Lipase inhibition rate (%)
Kale (Brassicaceae) 76.0
Cabbage (Brassicaceae) 44.0
Chinese cabbage (Brassicaceae) 31.6
Spicy radish (Brassicaceae) 43.8
Eggplant (Solanum) 57.1
Pumpkin (Cucurbitaceae) 2.9

  All other vegetables had low lipase inhibitory activity. Even the same cruciferous vegetables had little activity except for kale. Thus, in the present invention, Kale's surprising lipase inhibitory activity was found.

<Powder>
(Prescription)
(1) Lipase inhibitor of the present invention (Extract of Test Example 7) 2 parts by mass (2) Dry corn starch 38 parts by mass (3) Microcrystalline cellulose 60 parts by mass (production method) (1) to (3) Each 2 g was sealed to obtain a powder.

<Tablets>
(Prescription)
(1) Lipase inhibitor of the present invention (extract of Test Example 7) 15 parts by mass (2) Lactose 80 parts by mass (3) Synthetic aluminum silicate 4 parts by mass (4) Magnesium stearate 1 part by mass (production method)
The above components were mixed, and the mixture was tableted into 300 mg tablets with a tableting machine to obtain tablets.

<Liquid>
(Prescription)
(1) Lipase inhibitor of the present invention (Extract of Test Example 7) 110 g
(2) Erythritol 200g
(3) Sucralose 2g
(4) Citric acid 28g
(5) Malic acid 20g
(6) Sodium benzoate 4g
(7) Butyl paraoxybenzoate 0.3g
(8) 0.7 g of ethyl paraoxybenzoate
(9) Perfume appropriate amount (10) Purified water Appropriate amount (production method)
(2) to (8) were dissolved in 6 L of purified water by heating and then cooled, (1), (2) and (9) were added at around 50 ° C., and purified water was further added to make 10 L. 100 mL of this solution was dispensed into a container.

<Margarine>
(Prescription)
(1) rapeseed oil 81.2 parts by mass
(2) Water 10.0 parts by mass (3) Sodium chloride 1.5 parts by mass (4) Nonfat dry milk 2.0 parts by mass (5) Lecithin 0.3 parts by mass (6) Lipase inhibitor of the present invention (Test Example 7) 5.0 parts by mass (7) perfume appropriate amount (8) colorant appropriate amount
(Manufacturing method)
Manufactured in a conventional manner.

<Moisturizing cream>
(Prescription)
Oil phase component;
Jojoba oil 3.0% by mass
Liquid paraffin 4.0% by mass
POE (40) hydrogenated castor oil 2.0% by mass
Myristic acid isostearic acid diglyceride 15.0% by mass
Methylphenylpolysiloxane 5.0% by mass
Perfume appropriate amount water phase component;
Stearoyl methyl taurine sodium 0.5% by mass
Glycerin 20.0% by mass
Methylparaben 0.1% by mass
Lipase inhibitor of the present invention (extract of Test Example 7) 5.0% by mass
Purified water residue (production method)
The aqueous phase component was heated and mixed and kept at 70 ° C. The oil phase component was similarly dissolved by heating at 70 ° C. The above aqueous phase was added to the oil phase, emulsified with an emulsifier, and cooled to 25 ° C.

It is the figure which showed the preparation method of each preliminary sample used for this invention. FIG. 6 is a diagram showing an infrared analysis result of Sample 2. FIG. 6 is a diagram showing the result of infrared analysis of sample 6. It is the figure which showed the infrared analysis result of the sample 7. FIG. FIG. 6 is a diagram showing a liquid chromatography analysis result of Sample 2. FIG. 6 is a diagram showing a liquid chromatography analysis result of Sample 6. FIG. 6 is a view showing a liquid chromatography analysis result of Sample 7. It is the figure which compared the body weight change of the rat which administered each sample. It is the figure which showed the result of the blood test of the rat which administered each sample.

Claims (4)

  A lipase inhibitor comprising, as an active ingredient, a lower alcohol extract of a pretreated kale that is a kale from which water-soluble components have been removed or a dried product thereof. A pretreatment step of immersing kale or a dried product thereof in water and distributing it to water-soluble components and residues;
A method for producing a lipase inhibitor, comprising: an alcohol extraction step of immersing the residue in a lower alcohol and extracting an active ingredient with the lower alcohol.   3. The method for producing a lipase inhibitor according to claim 2, wherein the alcohol extraction step is a step of performing heat extraction with ethanol having an ethanol concentration of 60 to 80% by volume. An anti-obesity composition comprising the lipase inhibitor according to claim 1.

Images